| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1019425131 |
| P356 | DOI | 10.2165/00003088-199222050-00003 |
| P8608 | Fatcat ID | release_rvdundlu4vbmpc6rwfk7mzrfku |
| P698 | PubMed publication ID | 1505142 |
| P2093 | author name string | R. J. Kandrotas | |
| P2860 | cites work | Heparin clearance in the newborn | Q70839484 |
| Laboratory monitoring of heparin. Effect of reagents and instruments on the activated partial thromboplastin time | Q70930647 | ||
| In vitro and in vivo studies of the anti-Xa activity of heparin | Q71091747 | ||
| Determination of the biological activity of heparin by use of a chromogenic substrate | Q71172210 | ||
| Low-affinity heparin potentiates the action of high-affinity heparin oligosaccharides | Q71373640 | ||
| Heparin kinetics: variables related to disposition and dosage | Q71509204 | ||
| The inhibition by heparin of the intrinsic pathway activation of factor X in the absence of antithrombin-III | Q71539956 | ||
| Structural studies on a biologically active hexasaccharide obtained from heparin | Q72017116 | ||
| Control of heparin therapy. Sensitivity of the activated partial thromboplastin time for monitoring the antithrombotic effects of heparin | Q72336139 | ||
| A retrospective study of the pharmacokinetics of heparin | Q72414396 | ||
| Intersubject variability in the anticoagulant response to heparin in vitro | Q72665048 | ||
| Placental transport of heparin | Q72726823 | ||
| The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies | Q78981048 | ||
| The elimination from plasma of intravenous heparin. An experimental study on dogs and humans | Q79455782 | ||
| White clot syndrome. Peripheral vascular complications of heparin therapy | Q28326446 | ||
| Heparin-induced thrombocytopenia, thrombosis, and hemorrhage | Q28366919 | ||
| Heparin-associated thrombocytopenia treatment with low molecular weight heparin. | Q33455624 | ||
| Venous gangrene associated with heparin-induced thrombocytopenia | Q33459454 | ||
| Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin (CY 216). | Q33460399 | ||
| Heparin-related immune thrombocytopenia. Studies of antibody-heparin specificity | Q33491561 | ||
| Rapid determination of maintenance heparin infusion rates with the use of non-steady-state heparin concentrations | Q33493508 | ||
| Thrombocytopenia occurring during the administration of heparin. A prospective study in 52 patients | Q33501249 | ||
| Heparin assay methods for control of in vivo heparin effects | Q33980018 | ||
| Kinetics of the heparin-enhanced antithrombin III/thrombin reaction. Evidence for a template model for the mechanism of action of heparin. | Q34278340 | ||
| Heparin-induced platelet aggregation: dose/response relationships for a low molecular weight heparin derivative (PK 10169) and its subfractions | Q34691916 | ||
| Low-molecular-weight heparin and prevention of postoperative deep vein thrombosis | Q34747527 | ||
| Actions and Interactions of Antithrombin and Heparin | Q35148665 | ||
| Oral heparin results in the appearance of heparin fragments in the plasma of rats | Q35602982 | ||
| Evaluation of critical groups required for the binding of heparin to antithrombin | Q36248809 | ||
| Evidence for a 3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin | Q36414932 | ||
| Chemistry of heparin and low molecular weight heparin | Q39285421 | ||
| Pharmocokinetics of heparin. Distribution and elimination | Q39319685 | ||
| Inhibition of activated factor XII by antithrombin-heparin cofactor | Q39404087 | ||
| Haemorrhagic complications of heparin therapy | Q39437791 | ||
| A catalytic role for heparin. Evidence for a ternary complex of heparin cofactor thrombin and heparin | Q39496257 | ||
| Preventive and therapeutic approach to venous thromboembolic disease and pulmonary embolism--can death from pulmonary embolism be prevented? | Q39749124 | ||
| Pharmacokinetics and pharmacodynamics of heparin during hemodialysis: interpatient and intrapatient variability | Q68595584 | ||
| Heparin half-life in normal and impaired renal function | Q68791168 | ||
| Evidence for a saturable mechanism of disappearance of standard heparin in rabbits | Q69251026 | ||
| Low molecular weight heparin Novo (LHN-1) does not cross the placenta during the second trimester of pregnancy | Q69352640 | ||
| Heparin pharmacokinetics during hemodialysis | Q69400974 | ||
| Heparin dosage adjustment in patients with deep-vein thrombosis using heparin concentrations rather than activated partial thromboplastin time | Q69420720 | ||
| Comparative studies of heparin and heparin fragments: distribution and toxicity in the rat | Q69568970 | ||
| Variability in heparin sensitivity of APTT reagents | Q69583210 | ||
| Pharmacokinetics of intravenously and subcutaneously administered Fragmin in healthy volunteers | Q69590903 | ||
| Heparin fractions with high and low affinities to antithrombin III are cleared at different rates | Q69629923 | ||
| Selective binding of heparins to human endothelial cells. Implications for pharmacokinetics | Q69808218 | ||
| Pharmacokinetics of fragmin. A comparative study in the rabbit of its high and low affinity forms for antithrombin | Q69815397 | ||
| Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance | Q69817892 | ||
| [Absence of transplacental passage of Fraxiparin (low molecular weight heparin) during the 3d trimester of pregnancy] | Q69827759 | ||
| Binding, internalization and degradation of heparin and heparin fragments by cultured endothelial cells | Q69829658 | ||
| Pharmacokinetics of low molecular weight heparins | Q69842395 | ||
| Binding and endocytosis of heparin by human endothelial cells in culture | Q70105328 | ||
| Heparin treatment of deep vein thrombosis. Effects and complications after continuous or intermittent heparin administration | Q70223156 | ||
| Heparin kinetics determined by three assay methods | Q70263995 | ||
| Study on the mechanism of action of heparin and related substances on the fibrinolytic system: relationship between plasminogen activators and heparin | Q70296483 | ||
| Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis | Q70439876 | ||
| Absence of heparin or heparin-like compounds in mast-cell-free tissues and animals | Q70473126 | ||
| Kinetics of intravenously administered heparin in normal humans | Q70507033 | ||
| Disposition and anticoagulant activity of biologically active heparin fragments in the rat | Q70651773 | ||
| Heparin therapy in venous thromboembolism | Q70715038 | ||
| Management of heparin therapy: Controlled prospective trial | Q66893951 | ||
| Catabolism of low-dose heparin in man | Q66917440 | ||
| Kinetics of technetium-labeled heparin in thromboembolism: Preliminary report | Q66985394 | ||
| Binding of heparin on the surface of cultured human endothelial cells | Q67015932 | ||
| Heparin elimination in patients with liver cirrhosis | Q67024693 | ||
| Decreased binding of heparin to antithrombin following the interaction between antithrombin and thrombin | Q67057395 | ||
| Heparin-induced thrombocytopenia | Q67315235 | ||
| Evidence for the formation of an ester between thrombin and heparin cofactor | Q67321043 | ||
| Inhibition of human factor IXa by human antithrombin | Q67340338 | ||
| Heparin pharmacokinetics: increased requirements in pulmonary embolism | Q67350817 | ||
| Heparin kinetics in venous thrombosis and pulmonary embolism | Q67438323 | ||
| Assay of heparin in plasma using a chromogenic substrate for activated factor X | Q67446600 | ||
| The separation of active and inactive forms of heparin | Q67447965 | ||
| The fate of heparin in the body | Q67511069 | ||
| Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III | Q67566492 | ||
| A heparin-degrading endoglycosidase from rat spleen | Q67596991 | ||
| Heparin elimination in uraemic patients on Haemodialysis | Q67799847 | ||
| A Standard Heparin Nomogram for the Management of Heparin Therapy | Q67856239 | ||
| Effects of N-deacetylation and N-desulfation of heparin on its anticoagulant activity and in vivo disposition | Q67922137 | ||
| Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin iii and by gel filtration | Q68223412 | ||
| Studies on the antithrombotic effects and pharmacokinetics of heparin fractions and fragments | Q39815519 | ||
| Clinical use of intrapulmonary heparin | Q39828327 | ||
| The molecular-weight-dependence of the anti-coagulant activity of heparin | Q41045691 | ||
| Pharmacokinetics of heparin. I. Studies of dose dependence in rats | Q41691264 | ||
| Pharmacokinetics of heparin. II. Studies of time dependence in rats | Q41691269 | ||
| Endothelial binding sites for heparin. Specificity and role in heparin neutralization | Q41852417 | ||
| Heparin degradation in the endothelial cells | Q41913297 | ||
| Anticoagulant activity of heparin: Separation of high‐activity and low‐activity heparin species by affinity chromatography on immobilized antithrombin | Q42102840 | ||
| A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time | Q42236842 | ||
| Further characterization of the antithrombin-binding sequence in heparin | Q42263887 | ||
| The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin. | Q43442544 | ||
| Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis | Q43786633 | ||
| Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis | Q43834636 | ||
| Heparin therapy: a randomized prospective study | Q43911046 | ||
| The tPA-like activity induced by heparin and a heparin fragment binds on experimental thrombus | Q44246079 | ||
| Inactivation of the heparin anticoagulant activity by rat kidney lysosomal enzymes | Q44663172 | ||
| Pharmacokinetics of heparin and related polysaccharides | Q44686861 | ||
| Kinetics of Heparin Administration | Q45155323 | ||
| Antithrombotic effects of heparin oligosaccharides | Q46202208 | ||
| Selective distribution of the heparin in mammals: conspicuous presence of heparin in lymphoid tissues | Q46361992 | ||
| Biochemical and pharmacologic inequivalence of low molecular weight heparins | Q47175692 | ||
| The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. | Q47179980 | ||
| Kinetics of radiolabelled (99mTc) heparin and low molecular weight heparin fractions CY 216, CY 222 in patients with uncomplicated myocardial infarction | Q47188018 | ||
| The effect of molecular weight on the bioavailability of heparin | Q47189333 | ||
| The disappearance of a low molecular weight heparin fraction (CY 216) differs from standard heparin in rabbits | Q47194602 | ||
| Low molecular weight heparin half life is prolonged in haemodialysed patients | Q47207239 | ||
| Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers | Q47208131 | ||
| Efficacy and safety of two regimens of low molecular weight heparin fragment (Fragmin) in preventing postoperative venous thrombolism | Q47214662 | ||
| Heparin and its low molecular weight derivatives: anticoagulant and antithrombotic properties | Q47214672 | ||
| Pharmacokinetic studies of standard heparin and low molecular weight heparin in patients with chronic renal failure | Q47215021 | ||
| Relationship between biological activity and concentration of a low-molecular-weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration | Q47215036 | ||
| Increased anti-Xa bioavailability for a low molecular weight heparin (PK 10169) compared with unfractionated heparin | Q47222710 | ||
| Placental transport of low molecular weight heparin in the pregnant sheep | Q47230180 | ||
| Discordance between the anti-Xa activity and the antithrombotic activity in an ultra-low molecular weight heparin fraction | Q47262469 | ||
| The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits | Q47267859 | ||
| Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits | Q47269922 | ||
| Relationship between the antithrombotic and anticoagulant effects of low molecular weight heparin | Q47287004 | ||
| The measurement of heparin. A method based on the potentiation of anti-factor Xa. | Q47916561 | ||
| The Purification and Mechanism of Action of Human Antithrombin-Heparin Cofactor | Q47962380 | ||
| Plasma heparin: a unique, practical, submicrogram-sensitive assay | Q48017432 | ||
| The effect of heparin fragments of different molecular weights on experimental thrombosis and haemostasis | Q49165188 | ||
| The intracellular uptake and protracted release of exogenous heparins by cultured endothelial cells. | Q50891283 | ||
| The antithrombotic effect of heparin in deep venous thrombosis: relation to four heparin assays. | Q52432775 | ||
| Relationship between concentration and anticoagulant effect of heparin in plasma of hospitalized patients: magnitude and predictability of interindividual differences. | Q52434096 | ||
| Interindividual variation in relationships between plasma heparin concentration and the results of five heparin assays. | Q52434303 | ||
| Relationship between concentration and anticoagulant effect of heparin in plasma of normal subjects: magnitude and predictability of interindividual differences. | Q52435983 | ||
| Heparin with low affinity to antithrombin III inhibits the activation of prothrombin in normal plasma. | Q52505159 | ||
| The comparison of the pharmacokinetics of a low molecular weight heparin in the newborn and adult pig. | Q52514703 | ||
| Unfractionated heparin and CY 216: pharmacokinetics and bioavailabilities of the antifactor Xa and IIa effects after intravenous and subcutaneous injection in the rabbit | Q53406570 | ||
| Randomized prospective trial of continuous vs intermittent heparin therapy | Q54100966 | ||
| Heparin clearance and ex vivo recovery in newborn piglets and adult pigs. | Q54369527 | ||
| Anticoagulant Action of Heparin | Q59048517 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacodynamics | Q725307 |
| heparin | Q190016 | ||
| pharmacokinetics | Q323936 | ||
| P304 | page(s) | 359-74 | |
| P577 | publication date | 1992-05-01 | |
| P1433 | published in | Clinical Pharmacokinetics | Q5133788 |
| P1476 | title | Heparin pharmacokinetics and pharmacodynamics | |
| P478 | volume | 22 |
| Q41142601 | Activated clotting time versus activated partial thromboplastin time for therapeutic monitoring of heparin |
| Q37766083 | Anticoagulant and antithrombotic drugs in pregnancy: what are the anesthetic implications for labor and cesarean delivery? |
| Q42129756 | Capillary electrophoretic analysis of isolated sulfated polysaccharides to characterize pharmaceutical products |
| Q34734558 | Clinically important drug interactions with anticoagulants. An update |
| Q42630459 | Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects |
| Q47254719 | Delayed efficient anticoagulation with heparin in patients with a weight of 110 kg and more treated for acute coronary syndrome |
| Q35976822 | Dosing of unfractionated heparin in acute coronary syndromes. |
| Q47362437 | Drug delivery for bioactive polysaccharides to improve their drug-like properties and curative efficacy |
| Q44181879 | Fondaparinux sodium is not metabolised in mammalian liver fractions and does not inhibit cytochrome P450-mediated metabolism of concomitant drugs |
| Q37698254 | Heparin sensing: blue-chip binding |
| Q53325161 | Heparin-coated gold nanoparticles for liver-specific CT imaging. |
| Q70976482 | Heparinization for routine hemodialysis |
| Q45051137 | Higher Maximum Doses and Infusion Rates Compared with Standard Unfractionated Heparin Therapy Are Associated with Adequate Anticoagulation without Increased Bleeding in Both Obese and Nonobese Patients with Cardiovascular Indications |
| Q46862813 | Liver sinusoidal endothelial cells are the principal site for elimination of unfractionated heparin from the circulation |
| Q33410310 | Low-dose intravenous heparin infusion in patients with aneurysmal subarachnoid hemorrhage: a preliminary assessment |
| Q33502603 | Low-molecular-weight heparins in the treatment of deep-vein thrombosis |
| Q47387382 | Low-molecular-weight heparins: do good things really come in small packages? |
| Q26992262 | Measuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical review |
| Q32105118 | Monitoring of tinzaparin in a ten day treatment dose in elderly patients |
| Q33348524 | Nadroparin calcium. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders |
| Q33499002 | Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders |
| Q38871467 | Novel Treatments in Neuroprotection for Aneurysmal Subarachnoid Hemorrhage |
| Q33487898 | Parnaparin. A review of its pharmacology, and clinical application in the prevention and treatment of thromboembolic and other vascular disorders |
| Q35213469 | Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice |
| Q40905445 | Pharmacokinetic optimisation of the treatment of deep vein thrombosis |
| Q40504534 | Pharmacokinetic optimisation of the treatment of embolic disorders |
| Q45045888 | Pharmacokinetics of low molecular weight heparin and unfractionated heparin in pregnancy. |
| Q45337862 | Pharmacokinetics of the low molecular weight heparin dalteparin in cats |
| Q47393217 | Relationship between pharmacokinetics and pharmacodynamics of tinzaparin (logiparin), a low molecular weight heparin, in dogs |
| Q48154704 | Subcutaneous hematomas from prophylactic heparin use. |
| Q40472868 | Surrogate Biochemical Markers: Precise Measurement for Strategic Drug and Biologics Development |
| Q47342595 | The dose proportionality of the pharmacokinetics of ardeparin, a low molecular weight heparin, in healthy volunteers |
| Q46417236 | The safety of low molecular weight heparin therapy during labor |
| Q33488076 | Tinzaparin. A review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders |
| Q34448852 | Unfractionated heparin: multitargeted therapy for delayed neurological deficits induced by subarachnoid hemorrhage |
| Q47390135 | Use of a modified dosing weight for heparin therapy in a morbidly obese patient |
| Q36851934 | Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions |
| Q47424237 | β-Thromboglobulin may not reflect platelet activation during haemodialysis with the HeprAN membrane |
Search more.